Cargando…

Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer

INTRODUCTION: Breast cancer is a complex and heterogeneous disease which is increasingly important as a public health problem. In Brazil, 57,960 new cases have been estimated to be the burden in 2016 and 2017. Despite advances in early diagnosis and therapy, approximately 20-30% of patients, even wi...

Descripción completa

Detalles Bibliográficos
Autores principales: dos Santos, Giovana Tavares, Camillo, Natália Dressler, Berto, Maiquidieli Dal, Prolla, João Carlos, da Cruz, Ivana Beatrice Mânica, Roehe, Adriana Vial, Brackmann, Rosicler Luzia, Reiter, Keli Cristine, Bica, Claudia Giuliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747388/
https://www.ncbi.nlm.nih.gov/pubmed/29072390
http://dx.doi.org/10.22034/APJCP.2017.18.10.2673
_version_ 1783289263955116032
author dos Santos, Giovana Tavares
Camillo, Natália Dressler
Berto, Maiquidieli Dal
Prolla, João Carlos
da Cruz, Ivana Beatrice Mânica
Roehe, Adriana Vial
Brackmann, Rosicler Luzia
Reiter, Keli Cristine
Bica, Claudia Giuliano
author_facet dos Santos, Giovana Tavares
Camillo, Natália Dressler
Berto, Maiquidieli Dal
Prolla, João Carlos
da Cruz, Ivana Beatrice Mânica
Roehe, Adriana Vial
Brackmann, Rosicler Luzia
Reiter, Keli Cristine
Bica, Claudia Giuliano
author_sort dos Santos, Giovana Tavares
collection PubMed
description INTRODUCTION: Breast cancer is a complex and heterogeneous disease which is increasingly important as a public health problem. In Brazil, 57,960 new cases have been estimated to be the burden in 2016 and 2017. Despite advances in early diagnosis and therapy, approximately 20-30% of patients, even with early stage lesions, will develop distant metastatic disease. Tumors with similar clinical and pathological presentations may have differing behavior, so it is important to understand specific biological characteristics. OBJECTIVE: To investigate tumor markers of primary tumors featuring pleural metastasis to identify organ-specific characteristics of metastatic breast cancer. METHODS: In a historical cohort study, immunohistochemistry was performed on cell blocks of neoplastic pleural effusions and results were compared with clinicopathological data. RESULTS: The median survival time with Her-2 overexpression in malignant pleural effusions was 2.2 months, whereas cases without overexpression survived, on average, for seven months (p = 0.02). CONCLUSIONS: We emphasize that metastases may behave independently of primary tumors, but the present results indicate that therapeutic agents targeting Her-2 overexpression could increase survival in metastatic breast cancer cases.
format Online
Article
Text
id pubmed-5747388
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-57473882018-02-21 Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer dos Santos, Giovana Tavares Camillo, Natália Dressler Berto, Maiquidieli Dal Prolla, João Carlos da Cruz, Ivana Beatrice Mânica Roehe, Adriana Vial Brackmann, Rosicler Luzia Reiter, Keli Cristine Bica, Claudia Giuliano Asian Pac J Cancer Prev Research Article INTRODUCTION: Breast cancer is a complex and heterogeneous disease which is increasingly important as a public health problem. In Brazil, 57,960 new cases have been estimated to be the burden in 2016 and 2017. Despite advances in early diagnosis and therapy, approximately 20-30% of patients, even with early stage lesions, will develop distant metastatic disease. Tumors with similar clinical and pathological presentations may have differing behavior, so it is important to understand specific biological characteristics. OBJECTIVE: To investigate tumor markers of primary tumors featuring pleural metastasis to identify organ-specific characteristics of metastatic breast cancer. METHODS: In a historical cohort study, immunohistochemistry was performed on cell blocks of neoplastic pleural effusions and results were compared with clinicopathological data. RESULTS: The median survival time with Her-2 overexpression in malignant pleural effusions was 2.2 months, whereas cases without overexpression survived, on average, for seven months (p = 0.02). CONCLUSIONS: We emphasize that metastases may behave independently of primary tumors, but the present results indicate that therapeutic agents targeting Her-2 overexpression could increase survival in metastatic breast cancer cases. West Asia Organization for Cancer Prevention 2017 /pmc/articles/PMC5747388/ /pubmed/29072390 http://dx.doi.org/10.22034/APJCP.2017.18.10.2673 Text en Copyright: © Asian Pacific Journal of Cancer Prevention http://creativecommons.org/licenses/BY-SA/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
spellingShingle Research Article
dos Santos, Giovana Tavares
Camillo, Natália Dressler
Berto, Maiquidieli Dal
Prolla, João Carlos
da Cruz, Ivana Beatrice Mânica
Roehe, Adriana Vial
Brackmann, Rosicler Luzia
Reiter, Keli Cristine
Bica, Claudia Giuliano
Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
title Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
title_full Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
title_fullStr Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
title_full_unstemmed Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
title_short Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer
title_sort impact of her-2 overexpression on survival of patients with metastatic breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747388/
https://www.ncbi.nlm.nih.gov/pubmed/29072390
http://dx.doi.org/10.22034/APJCP.2017.18.10.2673
work_keys_str_mv AT dossantosgiovanatavares impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer
AT camillonataliadressler impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer
AT bertomaiquidielidal impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer
AT prollajoaocarlos impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer
AT dacruzivanabeatricemanica impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer
AT roeheadrianavial impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer
AT brackmannrosiclerluzia impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer
AT reiterkelicristine impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer
AT bicaclaudiagiuliano impactofher2overexpressiononsurvivalofpatientswithmetastaticbreastcancer